<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226599</url>
  </required_header>
  <id_info>
    <org_study_id>VP-P-2018-018</org_study_id>
    <nct_id>NCT04226599</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With DissolveAV</brief_title>
  <acronym>DissolveAVF</acronym>
  <official_title>Evaluation of the Safety and Efficacy of the Peripheral Scoring Drug Balloon (Dissolve AV) in Treatment of Hemodialysis Arteriovenous Fistulae Stenosis A Prospective Multicenter Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DK Medical Technology (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DK Medical Technology (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-coated balloons delivering paclitaxel at the angioplasty site have proved their&#xD;
      superiority in the treatment of coronary and peripheral arterial stenoses. Paclitaxel reduces&#xD;
      neointimal hyperplasia, therefore, it represents an attractive option for AVF stenoses. This&#xD;
      trial is aimed to evaluate the safety and efficacy of Peripheral scoring drug balloon&#xD;
      (Dissolve AV) or Balloon Dilatation catheter ( Armada 35) in treating AVF stenosis in chinese&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized controlled, open-label, superiority study. A&#xD;
      total of 220 subjects will be enrolled from 10 sites in China. All subjects enrolled will be&#xD;
      randomly assigned to the test group (Dissolve AV group, n=110) and the control group (Armada&#xD;
      35 group, n=110) with randomized allocation ratio of 1:1. Subjects in the test group and the&#xD;
      control group will be treated with Peripheral scoring drug balloon or Balloon Dilatation&#xD;
      catheter&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency rate of the target lesion at 6 month post procedure [ Target Lesion Primary Patency ]</measure>
    <time_frame>6 month</time_frame>
    <description>Target Lesion Primary Patency is defined as Target Lesion((+/-5mm proximal or distal of the target lesion)) failure(TLF) or target Vasculal Access Thrombosis. TLF is defined as target lesion stenosis(Stenosis rate&gt;30% by Digital Substraction Angiography(DSA)) result in insufficient hemodialysis flow (Refer to NKF-K/DOQIguideline) including: Venous pressure increased significantly during dialysis /Abnomal phenomenon physical examination/Decrease in pumping blood flow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency of target lesion in 12 months</measure>
    <time_frame>12 Month</time_frame>
    <description>Target Lesion Primary Patency is defined as Target Lesion((+/-5mm proximal or distal of the target lesion)) failure(TLF) or target Vasculal Access Thrombosis. TLF is defined as target lesion stenosis(Stenosis rate &gt;30% by Digital Substraction Angiography(DSA)) result in insufficient hemodialysis flow (Refer to NKF-K/DOQIguideline)including: Venous pressure increased significantly during dialysis /Abnomal phenomenon physical examination/Decrease in pumping blood flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>during the procedure</time_frame>
    <description>Successful delivery to the target lesion, deployment, and retrieval at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>5 days</time_frame>
    <description>The resumption of dialysis for at least one session after the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>2 weeks</time_frame>
    <description>residual stenosis≤30% and absence of SAE during perioperative perio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Fistulas Arteriovenous</condition>
  <arm_group>
    <arm_group_label>Dissolve AVF Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group treated with Peripheral scoring drug balloon.Dissolve AVF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group treated with plain balloon catheter.Armada 35</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dissolve AVF</intervention_name>
    <description>Subjects in the test group will be treated with peripheral scoring drug balloon.</description>
    <arm_group_label>Dissolve AVF Group</arm_group_label>
    <other_name>Using Peripheral scoring drug balloon catheter to cover the whole treated segment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Armada 35</intervention_name>
    <description>Subjects in the test group will be treated with plain balloon catheter.</description>
    <arm_group_label>PTA Group</arm_group_label>
    <other_name>Using plain balloon catheter to cover the whole treated segment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 75 years, male or female.&#xD;
&#xD;
          -  Arteriovenous fistula or Arteriovenous graft is matured and has undergone one or more&#xD;
             hemodialysis sessions&#xD;
&#xD;
          -  Venous stenosis of the AV fistula or AV graft&#xD;
&#xD;
          -  target lesion has stenosis ≥50% evidenced by angiography. and have at least one&#xD;
             symptom of these：1.Venous pressure increased significantly during dialysis,2.Abnomal&#xD;
             phenomenon physical examination,3.Decrease in pumping blood flow.&#xD;
&#xD;
          -  Target lesion consists of a single lesion or a multiple lesions with target lesion&#xD;
             length ≤ 40 mm. Reference vessel diameter of target lesion ≥ 4.0 mm and ≤ 7.0 mm.&#xD;
&#xD;
          -  If patient has non-target lesion, the stenosis ≥50% and don't need to be treated.&#xD;
&#xD;
          -  Patient able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant or are intending to become pregnant&#xD;
&#xD;
          -  AVF located at lower limbs&#xD;
&#xD;
          -  two or more than two stenosis at the target vessel.&#xD;
&#xD;
          -  Obstruction of central venous return&#xD;
&#xD;
          -  ISR&#xD;
&#xD;
          -  AVF with acute thrombosis requiring lysis or thrombectomy in 30 days&#xD;
&#xD;
          -  vascular access has surgery in 30 days or intending to undergo a surgery&#xD;
&#xD;
          -  known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,&#xD;
             etc.&#xD;
&#xD;
          -  Patients undergoing immunotherapy or suspected / confirmed vasculitis&#xD;
&#xD;
          -  Patients with history of blood coagulation dysfunction and history of thrombocytopenic&#xD;
             purpura&#xD;
&#xD;
          -  Vascular access infection or systemic active infection&#xD;
&#xD;
          -  patients's life expectancy is less than 12 months&#xD;
&#xD;
          -  Renal transplantation has been planned or converted to peritoneal dialysis&#xD;
&#xD;
          -  Other medical conditions that lead to researchers who believe that patients may not be&#xD;
             able to follow the trial program&#xD;
&#xD;
          -  involved in other drugs, biology, medical device research, or has been involved in&#xD;
             other similar products clinical Test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YE CHAOYANG</last_name>
    <role>Study Chair</role>
    <affiliation>ShuGuang Hospital affiliated to Shanghai University of Traditional Chinese</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YE CHAOYANG, MD</last_name>
    <phone>13801875009</phone>
    <email>yechaoyang63@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emergency general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SHI ZHENWEI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LI XUEMEI</last_name>
    </contact>
    <contact_backup>
      <last_name>LIU BINGYAN</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tongren hospital, Capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YU ZHENGYA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LIU YANGDONG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ShuGuang Hospital affiliated to Shanghai University of Traditional Chinese</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YE CHAOYANG, MD</last_name>
      <phone>13801875009</phone>
      <email>yechaoyang63@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan hospital affiliated to FuDan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SHI ZHENWEI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SHI YAXUE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiyuan Central Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MA DENGFENG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaoyifu hospital, zhejiang medical universiyt</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LI HUA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHEN JIANGHUA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis scoring Fistulas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

